8-K ·Filed Apr 10, 2026

LGVN

Longeveron Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001213900-26-042565
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor upcoming financial filings for disclosure of the exact number of RSUs granted and associated compensation expense. The move signals stabilized cash flow post-financing, but the dilutive impact of new equity grants could pressure shares if revenue growth doesn't follow.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
LGVN ▼ -42.59% at T+60d
NEUTRAL call ✗ call lost -42.59% · α vs SPY -51.51% · entry $1.12 → $0.6430
Entry anchored
Apr 10, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -1.21%
$1.12
settled 6mo ago
T+5d
-7.14%
call -7.14% · α -10.44%
$1.04
settled 6mo ago
T+20d
-25.18%
call -25.18% · α -32.91%
$0.8380
settled 5mo ago
T+60d
-42.59%
call -42.59% · α -51.51%
$0.6430
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Longeveron Inc. restored executive and board compensation after a temporary reduction and approved restricted stock unit (RSU) grants totaling 250,000 for each executive (500,000 for the CEO) as a reward for securing financing. The RSUs will vest quarterly over three years starting July 1, 2026.

Key Facts

  • Temporary executive and board compensation reductions (25%-50%) were reversed after successful financing closed on March 12, 2026
  • Each executive (except Executive Chairman) will receive 250,000 RSUs; the CEO will receive 500,000 RSUs
  • RSU grants will be issued on May 1, 2026, and vest quarterly over three years starting July 1, 2026
  • Compensation adjustments were made due to prior cash runway concerns, now resolved by financing

Financial Impact

Restoration of prior compensation levels and issuance of up to 1.25 million RSUs (exact value depends on stock price at grant date)

compensation expenseshare dilutioncash flow

Risk Factors

  • Potential share dilution from issuance of up to 1.25 million RSUs
  • No assurance of sustained financial stability if future capital raises are needed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-042565
Document: 0001213900-26-042565-index-headers.html0001213900-26-042565
Document: 0001213900-26-042565-index.html0001213900-26-042565
Document: 0001213900-26-042565.txt0001213900-26-042565
12 reports for LGVN
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +42.59%Apr 10, 2026
Filters
Rows
Reports for LGVN — sortable, filterable
TypeNow
Sep 14, 2026
17d ago
8-K
BULLISH ★ 5/10
$6.86 $2.49▼ −63.70%▼ −64.52%$2.57 (−62.61%)
Jul 13, 2026
11w ago
3
NEUTRAL ★ 2/10
$0.6223 $0.6022▼ −3.23%▼ −1.93%$2.57 (+312.18%)
Jun 5, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$0.7540 $0.7900▲ +4.77%▲ +2.66%$2.57 (+240.19%)
May 20, 2026
19w ago
Press Release
NEUTRAL ★ 4/10
$0.7210 $0.8150▲ +13.04%▲ +11.44%$2.57 (+255.76%)
May 13, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$0.7030 $0.7210▲ +2.56%▲ +3.28%$2.57 (+264.86%)
May 8, 2026
20w ago
8-K
BEARISH ★ 7/10
$0.8380 $0.6760▲ +19.33%▲ +19.25%$2.57 (−206.09%)
Apr 20, 2026
23w ago
EFFECT
BEARISH ★ 6/10
$1.04 $0.9000▲ +13.46%▲ +14.37%$2.57 (−146.63%)
Apr 10, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$1.12 $1.04▼ −7.14%▼ −10.44%$2.57 (+129.02%)
Apr 10, 2026
24w ago
S-1
BEARISH ★ 6/10
$1.12 $1.04▲ +7.14%▲ +10.44%$2.57 (−129.02%)
Mar 17, 2026
28w ago
Press Release
BEARISH ★ 7/10
$0.9760 $0.9730▲ +0.31%▼ −0.41%$2.57 (−162.81%)
Showing 10 of 12

US Market Status

Market Open — Closes in 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access